<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Zhang W</submitter><pubmed_abstract>&lt;b>Background:&lt;/b> Recent studies have identified that transglutaminases (TGMs) are involved in a widespread epigenetic modification in tumorigenesis. However, it remains unclear how transglutaminase 3 (TGM3) affects in pan-cancer. The present study aimed to explore the clinical and prognostic function of TGM3 in pan-cancer as well as to explore the relationship of TGM3 expression with clinical stage, survival rate, prognosis condition, immune infiltration and mutation indicators. &lt;b>Methods:&lt;/b> The relevant data of tumors were obtained from The Cancer Genome Atlas (TCGA), TARGET, Cancer Cell Line Encyclopedia (CCLE) and Genotype-Tissue Expression (GTEx) databases. According to the Human Protein Atlas (HPA) and TIMER databases, we evaluated the protein expression levels of TGM3 in differe</pubmed_abstract><journal>Frontiers in genetics</journal><pagination>993438</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9852731</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.</pubmed_title><pmcid>PMC9852731</pmcid><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Deng D</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Wu C</pubmed_authors><pubmed_authors>Zhou W</pubmed_authors><pubmed_authors>Zhou K</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.</name><description>&lt;b>Background:&lt;/b> Recent studies have identified that transglutaminases (TGMs) are involved in a widespread epigenetic modification in tumorigenesis. However, it remains unclear how transglutaminase 3 (TGM3) affects in pan-cancer. The present study aimed to explore the clinical and prognostic function of TGM3 in pan-cancer as well as to explore the relationship of TGM3 expression with clinical stage, survival rate, prognosis condition, immune infiltration and mutation indicators. &lt;b>Methods:&lt;/b> The relevant data of tumors were obtained from The Cancer Genome Atlas (TCGA), TARGET, Cancer Cell Line Encyclopedia (CCLE) and Genotype-Tissue Expression (GTEx) databases. According to the Human Protein Atlas (HPA) and TIMER databases, we evaluated the protein expression levels of TGM3 in differe</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-22T09:04:22.16Z</modification><creation>2025-04-05T22:51:38.205Z</creation></dates><accession>S-EPMC9852731</accession><cross_references><pubmed>36685895</pubmed><doi>10.3389/fgene.2022.993438</doi></cross_references></HashMap>